Loading...
•
Dec 31, 2023
Aadi Bioscience Q4 2023 Earnings Report
Aadi Bioscience's Q4 2023 earnings were announced, highlighting growth in FYARRO sales and progress in clinical trials.
Key Takeaways
Aadi Bioscience reported Q4 2023 revenue of $6.3 million from FYARRO sales, a 21% increase year-over-year. The company's net loss for the quarter was $16.3 million. They are on track with their PRECISION1 trial and initiated enrollment in two Phase 2 trials.
FYARRO net product sales reached $6.3 million in Q4 2023, representing a 21% year-over-year growth.
The PRECISION1 trial is on track to complete enrollment by May 2024, with an interim analysis expected in Q3 2024.
Enrollment has begun for two Phase 2 trials investigating nab-sirolimus for neuroendocrine tumors (NETs) and advanced or recurrent endometrioid-type endometrial cancer (EEC).
Cash, cash equivalents, and short-term investments totaled $108.8 million as of December 31, 2023, expected to fund operations into Q4 2025.
Aadi Bioscience
Aadi Bioscience
Aadi Bioscience Revenue by Segment
Revenue by Segment
Product Sales, Net Revenue
CapyFin.com Forward Guidance
Aadi Bioscience anticipates continued advancements and growth, with expectations surrounding the timing of clinical trials and potential additional indications for FYARRO.
Positive Outlook
- Cash runway extending into the fourth quarter of 2025.
- PRECISION 1 trial on track to complete enrollment by May 2024.
- PRECISION 1 two-thirds interim analysis expected in Q3 2024.
- Potential for additional indications for FYARRO.
- Continued advancements and growth expected.
Challenges Ahead
- Uncertainties associated with clinical development and regulatory approval of FYARRO in additional indications.
- Potential delays in clinical trials for additional indications.
- Risk of unforeseen adverse reactions or side effects during commercialization and development.
- Reliance on third-party suppliers, some of which are sole suppliers.
- Risks related to estimates regarding future expenses, capital requirements, and the need for additional financing.